Operations and clinical assesment core

运营和临床评估核心将负责将CIDAR科学和临床评估 基础设施目标。卡彭特博士(私家侦探)拟议的指导委员会将总体上 负责CIDAR的行政职能。指导委员会将包括主要的科学研究人员 本申请的领导：凯尼格博士(P.I.：临床前研究核心和项目#1)；Thaker博士(P.I.： 研究方法核心和项目2)；Conley博士和Buchanan博士(P.I./Co-P.I.：项目3)；McMahon博士 (生物统计学家；Co-P.I.：研究方法核心)；Gold博士(神经心理学家；Co-P.I.；研究 方法核心)。指导委员会将正式审查业务和临床评估核心， 研究方法核心、临床前研究核心和研究项目活动每六个月一次。这个 指导委员会还将负责促进博士后研究员的参与 以及参加CIDAR活动的初级教员。在与NIMH计划工作人员协商后，核心将建立一个 设立外部咨询委员会，并在开始时与顾问会面，以审查计划。外在的 咨询委员会将包括来自学术界和工业界的药物发现和开发专家 实验室，与这一应用相关的特别评估专家，以及一名生物统计学专家。 核心临床评估部分将由以下内容组成：1)生物统计和数据 管理股(BDM)，将由Robert McMahon博士领导，并将在 统计咨询和数据库管理；和2)临床评估股，该股将由 临床评估股将提供：a)可靠和有效的诊断 程序；b)可靠和有效的工具，用于评估症状、认知功能和社会和 职业职能；c)使用这些工具的培训，以及方案内和方案间持续进行的培训 可靠性会议，以最大限度地保持评级的一致性，并控制评分员的漂移；以及d)科目征聘 服务。

The Operation and Clinical Assessment Core will be responsible for integrating the CIDAR scientific and infrastructure aims. Dr. Carpenter (the P.I.) and the proposed Steering Committee will have overall responsibility for the CIDAR administrative functions. The Steering Committee will include the key scientific leadership for this application: Dr. Koenig (P.I.: Pre-clinical Studies Core and Project #1); Dr. Thaker (P.I.: Research Methods Core and Project #2); Drs. Conley and Buchanan (P.I./Co-P.I.: Project #3); Dr. McMahon (Biostatistician; Co-P.I.: Research Methods Core); and Dr. Gold (Neuropsychologist; Co-P.I.; Research Methods Core). The Steering Committee will formally review the Operation and Clinical Assessment Core, Research Methods Core, and Pre-Clinical Studies Core and research project activities every six months. The Steering Committee will also be responsible for facilitating the involvement of post-doctoral research fellows and junior faculty in CIDAR activities. In consultation with NIMH program staff, the Core will establish an External Advisory Committee and meet with the advisors at the outset to review plans. The External Advisory Committee will include experts in drug discovery and development from academic and industry labs, experts in special assessments relevant to this application, and an expert in biostatistics. The Clinical Assessment component of the Core will be comprised of a: 1) Biostatistics and Data Management Unit (BDM), which will be directed by Robert McMahon, Ph.D. and will provide services in statistical consulting and database management; and 2) Clinical Assessment Unit, which will be directed by Robert W. Buchanan, M.D. The Clinical Assessment Unit will provide: a) reliable and valid diagnostic procedures; b) reliable and valid instruments for assessing symptoms, cognitive function, and social and occupational function; c) training in the use of these instruments, and ongoing intra- and inter-program reliability sessions to maximize consistency in ratings and to control for rater drift; and d) subject recruitment services.